‘Polypill’ Trinomia reduces deaths from heart disease: study

One pill may be better than three.

According to the findings of a study announced on Friday August 26 at the Congress of the European Society of Cardiology (ESC 2022) in Barcelona, ​​Spain.

The cardiovascular mortality rate was lowered by 33%, according to the study.

Published in the New England Journal of Medicine, the study found that the drug, with the trade name Trinomia, contains three drugs: aspirin (100mg), the angiotensin-converting enzyme inhibitor ramipril (2.5, 5 or 10 mg) and atorvastatin. (20 or 40 mg), according to a press release.

The Spanish National Cardiovascular Research Center (CNIC) and Ferrer developed the polypill.

Currently, the polypill is not available in the United States.

Dr. Valentin Fuster, MD, director of Mount Sinai Heart and chief medical officer of Mount Sinai Hospital as well as chief executive of CNIC, led the trial.

The results of the study demonstrate “for the first time that the polypill – which contains aspirinramipril and atorvastatin – provide clinically relevant reductions in recurrent cardiovascular events in people who have recovered from a previous heart attack,” he said in the statement.

The new heart drug known as
The new heart drug “polypill” has reduced the risk of a secondary adverse cardiovascular event for those who have already had a heart attack.
REUTERS / Magali Druscovitch

It is “because of better adherence to this simplified approach with a simple polypill, rather than taking [pills] separately as conventional,” he continued.

Typically, after a patient recovers from a heart attack, doctors prescribe several medications, which may include an antiplatelet agent (such as aspirin), a drug to control blood pressure, and a lipid-lowering drug. as a statin, according to the release. .

The problem is that less than half of patients consistently adhere to their medication regimen, according to the study authors.

“Although most patients initially adhere to treatment after an acute event such as a heart attack, adherence declines after the first few months,” Dr. Fuster said in the statement.

He also explained, “Our goal was to have an impact early on, and most patients in the study started taking a simple polypill within the first week after having a heart attack.”

The study’s first author, Dr. José María Castellano, MD, said in the report, “Adherence to treatment after acute myocardial infarction is essential for effective secondary prevention.”

Castellano also said in the statement: “The polypill, [which is] a very simple strategy that combines three essential treatments for this type of patient has proven itself… Improved compliance means that these patients receive better treatment and therefore have a lower risk of recurrent cardiovascular events.

In a previous study published in the Journal of the American College of Cardiology (JACC), CNIC scientists showed that patients treated with the polypill showed significant improvement in treatment adherence.

Dr. Valentin Fuster, Mount Sinai Hospital's chief medical officer and CNIC's chief executive, led the trial of the drug.
Dr. Valentin Fuster, chief medical officer at Mount Sinai Hospital, led the trial of the drug.
aubrey ruben

The CNIC team of researchers studied whether improving adherence to treatment with the polypill would lead to a reduction in cardiovascular events.

The study used an international randomized clinical trial that included 2,499 patients from seven European countries recovering from a heart attack.

Participants were randomly given the CNIC polypill or the standard treatment drugs. Participants were on average 76 years old – and the study included people with a history of high blood pressure (77.9%), diabetes (57.4%) and smoking (51.3%).

The team of researchers followed the patients for an average of three years.

They analyzed the occurrence of four major cardiovascular events: cardiovascular death, nonfatal stroke, nonfatal myocardial infarction, and the need for emergency coronary revascularization, the report said.

They found that patients taking the polypills had a 24% lower risk of these four cardiovascular events than patients taking the three drugs separately, according to the release.

The researchers found that there were 71 deaths in the standard treatment group, compared to 48 in the polypill group.

Patients in the polypill group also had a higher level of treatment adherence than those in the control group – which may explain the benefits of the polypill, the statement said.

“The 33% reduction in cardiovascular mortality demonstrates the efficacy of treatment with Trinomia compared to standard therapy,” said Oscar Pérez, Chief Marketing Officer and Business Development Manager at Ferrer, in the release.

The treatment has the “potential to reduce the risk of recurrent cardiovascular disease and death globally”.

“These results ratify our goal to have a positive impact on society and represent an important step in our mission to provide meaningful and differential value to people with serious health conditions.”

The polypill could be part of a global treatment strategy, Fuster said, to help prevent recurrent cardiovascular events in patients who have had a heart attack.

Fuster also said, “By simplifying treatment and improving adherence,” this approach has the “potential to reduce the risk of recurrent cardiovascular disease and death globally.”

A Mount Sinai Health Systems spokesperson told Fox News Digital that Fuster plans to present the results to the US Food and Drug Administration (FDA).

Leave a Comment